| Kenneth Scott Knox, MD | |
|
1501 N Campbell Ave, Tucson, AZ 85724-0001 | |
| (520) 694-8888 | |
| (520) 694-2353 |
| Full Name | Kenneth Scott Knox |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 30 Years |
| Location | 1501 N Campbell Ave, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154386118 | NPI | - | NPPES |
| 200295280 | Medicaid | IN | |
| 398969 | Medicaid | AZ |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner - University Physician Specialists Llc | 5991008054 | 233 |
| Banner -- University Medical Group | 7719899871 | 819 |
News Archive
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a process that controls the amount of fat that cells store for use as a back-up energy source.
A new web-based support programme will help reduce the psychological stress that impacts men who are recovering from prostate cancer.
Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.
› Verified 4 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a process that controls the amount of fat that cells store for use as a back-up energy source.
A new web-based support programme will help reduce the psychological stress that impacts men who are recovering from prostate cancer.
Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.
› Verified 4 days ago
| Entity Name | Banner - University Physician Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437529245 PECOS PAC ID: 5991008054 Enrollment ID: O20160122001476 |
News Archive
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a process that controls the amount of fat that cells store for use as a back-up energy source.
A new web-based support programme will help reduce the psychological stress that impacts men who are recovering from prostate cancer.
Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.
› Verified 4 days ago
| Entity Name | Banner - University Super Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740650555 PECOS PAC ID: 1850695255 Enrollment ID: O20160204002443 |
News Archive
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a process that controls the amount of fat that cells store for use as a back-up energy source.
A new web-based support programme will help reduce the psychological stress that impacts men who are recovering from prostate cancer.
Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kenneth Scott Knox, MD 2701 E Elvira Rd, Tucson, AZ 85756-7124 Ph: (520) 874-3500 | Kenneth Scott Knox, MD 1501 N Campbell Ave, Tucson, AZ 85724-0001 Ph: (520) 694-8888 |
News Archive
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a process that controls the amount of fat that cells store for use as a back-up energy source.
A new web-based support programme will help reduce the psychological stress that impacts men who are recovering from prostate cancer.
Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.
› Verified 4 days ago
Dr. Basel Skeif, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5140 E Glenn St, Tucson, AZ 85712 Phone: 520-838-3540 Fax: 520-325-3526 | |
Dr. David Spencer Hamilton Sr., MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3601 S 6th Ave, Tucson, AZ 85723 Phone: 520-792-1450 | |
Diana Silva Cantillo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1230 S Cherrybell Stra, Tucson, AZ 85713 Phone: 520-628-8287 | |
Basel Shoua, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2070 W Rudasill Rd Ste 130, Tucson, AZ 85704 Phone: 520-797-4468 Fax: 520-797-4502 | |
Hadil Owaynat, DO Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1501 N Campbell Ave Rm 6336, Tucson, AZ 85724 Phone: 520-626-2760 Fax: 520-626-6020 | |
Dr. David M Schwartz, DO Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6200 N La Cholla Blvd, Tucson, AZ 85741 Phone: 520-469-8011 Fax: 520-469-8021 | |
Kenneth Alex Murachanian, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6060 N Fountain Plaza Dr Ste 270, Tucson, AZ 85704 Phone: 520-229-2578 |